Current and Emerging Glaucoma Therapies Webcast
Media formats available:
Details
Presenters
Overview
Supported by an educational grant from Aerie Pharmaceuticals Learning Objectives
Upon completion of this activity, the participant should be able to: • Discuss the chemical structure and mechanism of action of topical glaucoma medications and evolving neuroprotective medications • Explain the anti-fibrotic activity in novel drug classes • Evaluate novel therapeutics and classes of drugs and their potential for enhanced patient compliance Accreditation
Accreditation Statement Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. In cooperation with Evolve Medical Education, the University of Houston College of Optometry (UHCO) has reviewed and endorsed Current and Emerging Glaucoma Therapies. This course is COPE approved for 1.0 hour of CE credit(s) for optometrists COPE Course ID’s: 57106-GL COPE Activity ID: 115199 Faculty and Disclosures
DISCLOSURE POLICY
Robert D. Fechtner, MD Professor and Chair, Department of Ophthalmology SUNY Upstate Medical University, Syracuse, NY Jonathan S. Myers MD Co-Director, Glaucoma Service Wills Eye Hospital Philadelphia PA Robert D. Fechtner, MD has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Aerie Pharmaceuticals; Akorn Pharmaceuticals; and Novartis. Jonathan S. Myers MD has had a financial agreement or affiliation during the past year with the following commercial interest in the form of :;Consultant: Aerie Pharmaceuticals; Allergan plc; Glaukos; MicroOptx; and Novartis AG. Speaker: Aerie Pharmaceuticals; Allergan plc; and Novartis AG. Grant Research: Aerie Pharmaceuticals; Allergan plc; Diopsys; Heidelberg Pharma; Novartis AG; Shire plc; SightSource; and Carl Zeiss Meditec. Editorial Support DisclosuresErin K. Fletcher, MIT, director of compliance and education, Evolve; and Michelle Dalton, writer have no financial relationships with commercial interests. Rishi P. Singh, MD, peer reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Carl Zeiss Meditec; Genentech, Inc; Optos plc; and Regeneron Pharmaceuticals, Inc. Grant/Research Support: Apellis Pharmaceuticals; Clearside Biomedical; Genentech, Inc; Novartis AG; and Regeneron Pharmaceuticals, Inc.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.Disclaimer
Off-Label Statement This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Disclaimer The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, or Aerie Pharmaceuticals Inc. System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!